Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company focused on discovering and developing therapeutics for neuromuscular diseases. The company is developing a portfolio of muscle disease therapeutics, including programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease. It also targets rare skeletal muscle, cardiac, and metabolic muscle diseases using its proprietary FORCE platform, which delivers disease-modifying therapeutics. Dyne Therapeutics is headquartered in Waltham, Massachusetts, and was incorporated in 2017.

Dyne Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol DYN. The company trades in United States Dollars (USD), which is the currency of its home country. As a US-based company listed on a major US exchange, its stock is accessible to investors through standard brokerage accounts that trade on Nasdaq.

Dyne Therapeutics operates in the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology company, it focuses on research and development of therapies for neuromuscular diseases, which are often genetic or degenerative conditions affecting muscles and nerves. The company's work involves advanced drug discovery and clinical-stage development, typical of biotech firms that aim to bring novel treatments to market.

Dyne Therapeutics is headquartered in Waltham, Massachusetts, United States. The company primarily serves the United States market, as indicated by its country and region designation. Its focus is on developing therapeutics for neuromuscular diseases, which affect patients globally, but its operations and clinical programs are based in the US. The company was incorporated in 2017 and has since been advancing its pipeline of muscle disease treatments.

The FORCE platform is Dyne Therapeutics' proprietary technology used to deliver disease-modifying therapeutics for muscle diseases. This platform is central to the company's approach in developing treatments for conditions like myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease. By leveraging FORCE, Dyne aims to target specific muscle tissues and deliver therapies that can modify the course of these neuromuscular diseases. The platform represents a key part of the company's business model, as it enables the development of a diverse portfolio of muscle disease therapeutics.